Google
ARQT — ARCUTIS BIOTHERAPEUTICS INC (Healthcare >> Biotechnology)
ARQT FAQ
What is ARQT's P/E ratio?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) currently trades at a P/E ratio of 110.69.
What is ARQT's ROE?
ARCUTIS BIOTHERAPEUTICS INC reports a Return on Equity (ROE) of -1.25%.
What is ARQT's dividend yield?
ARCUTIS BIOTHERAPEUTICS INC offers a dividend yield of 0.00%.
What is ARQT's Deepscope Quality Score?
Deepscope rates ARQT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ARQT?
Deepscope's AI Timing Score for ARQT is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ARQT belong to?
ARCUTIS BIOTHERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 21.23
Price
-0.72
(-3.28%)
Day Change
|
|
|---|
ARQT, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 21.23 |
| PBV / Sector |
14.48 / 4.63
|
| Earning Per Share | -0.02 |
| PE / Sector |
110.69 / 17.43
|
| PEG or PE/Growth / Sector |
-1.73 / 0.53
|
| Average 1M Daily Value |
40.40 M
GREAT
|
| Average 1W Daily Value |
30.16 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:27 |
| Symbol | ARQT |
| Name | ARCUTIS BIOTHERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 125.08 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,745.58 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361
Phone: 805 418 5006
Website: https://www.arcutis.com
Employees: 354
Sector: Healthcare >> Biotechnology
Description: Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
